Clinical Trials Directory

Trials / Unknown

UnknownNCT05632068

Xian-Hua-Cha for Relieving Hyperlipidemia With Obesity

The Efficacy of Xian-Hua-Cha for Improving Hyperlipidemia Among Obese Population: a Crossover Trial

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Chang Gung Memorial Hospital · Academic / Other
Sex
All
Age
20 Years – 75 Years
Healthy volunteers
Accepted

Summary

In the past decades, lipid and body fat disorders become a serious global healthcare issue, especially among the obese population. The aim of this study is to include 100 selected patients with BMI higher than 27 and hyperlipidemia, and a crossover design is used to explore the efficacy of "Xian-Hua-Cha (XHC)" on relieving hyperlipidemia among obese patient. For this purpose, the changes of patients' body weight, body fat and the metabolic parameter including blood sugar, cholesterol, triglyceride are analyzed in the end of this study.

Detailed description

Recently, there are more and more studies show the natural herbal products can improve obesity and related metabolic disorders through changing the body composition and even body weight, but most of the studies are still at the phase of animal studies. In the ancient Chinese medical book Danxi's mastery of medicine mentioned "Overweight people often have phlegm." From the past observational study, obesity is related phlegm, and the recent concept shows that obesity is a chronic inflammation disease. Therefore, we combined phlegm removal herbal medicine and Chinese medicine for clearing heat and detoxifying together for obese patients with lipid disorders in clinical practice. The aim of this study is to include 100 selected patients with BMI higher than 27 and hyperlipidemia, and a crossover design is used to analyze the efficacy of "Xian-Hua-Cha (XHC)" on relieving hyperlipidemia among the obese population. For this reason, the changes of patients' body weight, body fat and the metabolic parameter including blood sugar, cholesterol, triglyceride are collected for analysis. Besides, we also record adverse effects from taking XHC to assess the safety of XHC.

Conditions

Interventions

TypeNameDescription
DRUGXian-Hua-ChaZizyphus jujuba Mill., Nelumbo nucifera Gaertn, Citrus reticulata Blanco, Rosa rugosa Thunb., Cassia obtusifolia L., Stevioside, resistant starch, and water

Timeline

Start date
2022-12-13
Primary completion
2024-12-31
Completion
2025-06-30
First posted
2022-11-30
Last updated
2024-10-08

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT05632068. Inclusion in this directory is not an endorsement.